Physician profile
Mark A Shapiro
NPI 1003914680
$14,945.48
in general payments reported to CMS, 2019-2025
41 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,465 · 2020: $1,914 · 2021: $2,331 · 2022: $2,253 · 2023: $2,075 · 2024: $1,919 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,982.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,295.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,792.71 | 2019-2025 | Wegovy, Saxenda |
| Astrazeneca Pharmaceuticals LP | $1,768.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,066.32 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $988.21 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $829.60 | 2021-2023 | |
| Glaxosmithkline, LLC. | $674.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $609.42 | 2022-2025 | |
| Pfizer INC. | $597.14 | 2019-2025 | |
| Amarin Pharma, INC. | $531.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $507.93 | 2023-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $368.54 | 2019-2022 | |
| Allergan, INC. | $271.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $263.99 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $246.25 | 2019-2024 | Livalo, Seglentis |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.